Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Candel Therapeutics (CADL) Accumulated Depreciation (2020 - 2025)

Candel Therapeutics' Accumulated Depreciation history spans 4 years, with the latest figure at $2.1 million for Q4 2023.

  • On a quarterly basis, Accumulated Depreciation rose 85.03% to $2.1 million in Q4 2023 year-over-year; TTM through Dec 2023 was $2.1 million, a 85.03% increase, with the full-year FY2023 number at $2.1 million, up 85.03% from a year prior.
  • Accumulated Depreciation hit $2.1 million in Q4 2023 for Candel Therapeutics, up from $1.8 million in the prior quarter.
  • Over the last five years, Accumulated Depreciation for CADL hit a ceiling of $2.1 million in Q4 2023 and a floor of $134000.0 in Q4 2020.
  • Historically, Accumulated Depreciation has averaged $915250.0 across 4 years, with a median of $806500.0 in 2022.
  • Biggest five-year swings in Accumulated Depreciation: soared 383.51% in 2022 and later surged 85.03% in 2023.
  • Tracing CADL's Accumulated Depreciation over 4 years: stood at $134000.0 in 2020, then surged by 162.69% to $352000.0 in 2021, then soared by 220.74% to $1.1 million in 2022, then surged by 85.03% to $2.1 million in 2023.
  • Business Quant data shows Accumulated Depreciation for CADL at $2.1 million in Q4 2023, $1.8 million in Q3 2023, and $1.6 million in Q2 2023.